Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma

NCT00435578 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Small Cell Lung

Interventions

DRUG: Glufosfamide

Sponsor

Threshold Pharmaceuticals